Thyrotropin-releasing hormone (TRH), also called thyrotropin-releasing factor (TRF), thyroliberin or protirelin, is a tropic tripeptide hormone that stimulates the release of thyroid-stimulating hormone and prolactin by the anterior pituitary.
Its structure is: (pyro)Glu-His-Pro-NH2
A TRH test may be indicated if secondary hypothyroidism is suspected. Some patients may have low levels of circulating thyroid hormones and secondary hypothyroidism as a result of damage to the hypothalamic or pituitary control mechanisms that regulate thyroid function. The hypothalamus makes a small hormone called TRH that directs the synthesis and secretion of TSH from the pituitary gland. If these normal regulatory mechanisms are interrupted, the pituitary may not be able to produce appropriate levels of TSH and levels of thyroid hormones may decline, although the TSH remains appropriately normal. The TRH test involves administration of a small amount of TRH intravenously, following which levels of TSH will be measured at several subsequent time points using samples of blood taken from a peripheral vein. Patients with normal function of the hypothalamic-pituitary axis (HPA) respond by increasing the levels of TSH following TRH injection. Patients with compromised HPA function may exhibit a delayed, blunted, or absent response to TRH administration. TRH may cause nausea, vomiting and some patients experience an urge to urinate. Rarely, TRH may cause blood vessel constriction leading to hemorrhage in patients with pre-existing pituitary tumors. Accordingly, patients should be advised about the risks, albeit rare, of TRH testing.
Subclinical hypothyroidism in infertile women: The importance of continuous monitoring and the role of the thyrotropin-releasing hormone stimulation test
Jun 01, 2007; Abstract The aim of our study was to assess the prevalence of subclinical hypothyroidism (SH) after administering a...